NCT02421939 2025-12-04
A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation
Astellas Pharma Inc
Phase 3 Completed
Clinical Trials
15 trialsNCT02310321 2025-09-02
A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia.
Astellas Pharma Inc
Phase 1/2 Completed
NCT02834390 2025-03-05
Study of Quizartinib in Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
Daiichi Sankyo
Phase 1 Completed
NCT02236013 2024-11-05
A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia
Astellas Pharma Inc
Phase 1 Completed
NCT02668653 2024-08-06
QuANTUM-First
Daiichi Sankyo
Phase 3 Completed
NCT02400281 2024-07-03
Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia Patients
Arog Pharmaceuticals, Inc.
Phase 1/2 Completed
NCT02626338 2023-12-20
Pilot Study of Crenolanib Combined With Standard Salvage Chemotherapy in Subjects With R/R AML
Arog Pharmaceuticals, Inc.
Phase 1/2 Completed
NCT02873338 2023-09-07
Dociparstat Sodium (CX-01) Combined With Standard Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia
Jazz Pharmaceuticals
Phase 2 Completed
NCT02835729 2020-06-04
A Study of Indoximod in Combination With (7+3) Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia
Lumos Pharma
Phase 1 Completed
NCT00620321 2019-09-09
A Study of LY2181308 Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Eli Lilly and Company
Phase 2 Completed
NCT02306291 2019-05-17
Study to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in AML
GlycoMimetics Incorporated
Phase 1/2 Completed
NCT01773408 2017-01-25
A Study of RO5503781 as a Single Agent or in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia
Hoffmann-La Roche
Phase 1 Completed
NCT00878722 2015-07-28
Trial of PXD101 (Belinostat) in Combination With Idarubicin to Treat AML Not Suitable for Standard Intensive Therapy
Valerio Therapeutics
Phase 1/2 Completed
NCT00074737 2014-09-18
Dosing Study of Ara-C/EL625/Idarubicin in Refractory and Relapsed AML
Eleos, Inc.
Phase 2 Completed
NCT01035502 2013-09-27
A Study of Elacytarabine (CP-4055) Plus Idarubicin as Second Course Remission-Induction Therapy in Patients With Acute Myeloid Leukaemia
Clavis Pharma
Phase 2 Completed